Search

Cookies

We use cookies to improve your experience. By continuing, you accept our use of cookies.

Business

Nomura Raises Lupin Target Price Amid US Sales Concerns, Citing Favorable Risk-Reward

· · 3 min read

Nomura has reaffirmed its 'Buy' rating for Lupin Ltd. and increased its target price to Rs 2,780, expecting a 40.6% upside. The brokerage believes near-term US sales declines are already factored into the stock's current valuation.

Financial services firm Nomura has reiterated its 'Buy' rating for Indian pharmaceutical major Lupin Ltd., simultaneously raising its target price to Rs 2,780 from the previous Rs 2,675. This revised target implies a significant upside of approximately 40.6% from Lupin's closing price of Rs 1,977 on November 16.

Despite anticipating near-term weakness in Lupin's crucial US business, Nomura views the company's current valuations as attractive. The brokerage suggests that concerns regarding declining US sales have largely been integrated into the stock's present valuation, creating a favorable risk-reward scenario over the next one to two years.

Lupin's Valuation and Market Performance

Lupin shares saw a high of Rs 1,993, marking a 2% increase from their prior close of Rs 1,953.90. The stock opened at Rs 1,960.40 and touched a low of Rs 1,946.60 during the trading session.

Nomura's target price is based on 30 times its estimated FY29 earnings per share of Rs 92.70. The brokerage noted that Lupin's valuation multiples are currently positioned towards the lower end of their six-year range. According to Bloomberg consensus estimates, the stock is trading at 11.8 times one-year forward EV/EBITDA and 20.5 times one-year forward price-to-earnings.

Anticipated US Market Headwinds

Nomura projects a near-term decline in Lupin's US sales due to intensified competition for three key products: gJynarque, gMyrbetriq, and gSpiriva Handihaler. These products collectively accounted for approximately 40% of Lupin's US revenue in the September 2026 quarter.

While expecting erosion, Nomura forecasts a slower decline than management's guidance, estimating FY27 US sales at $1.25 billion, surpassing the company's own guidance of $1.1 billion to $1.2 billion. The brokerage expects additional competition to impact gJynarque and gMyrbetriq sales, with pricing pressures affecting gSpiriva. Furthermore, Nomura has factored in lower base business sales in the US, currency fluctuations, slower growth in select markets like Brazil, and increased expenses. Consequently, Nomura has adjusted its earnings estimates for FY27, FY28, and FY29 downward by 14%, 2%, and 8%, respectively.

Strengths in Domestic Formulations and Pipeline

Despite the challenges in the US market, Nomura highlights several supporting factors for Lupin. These include the robust performance of its domestic formulations business, a strong balance sheet, and a promising pipeline of complex generics. The brokerage anticipates Lupin's India formulations business to grow 20-30% ahead of the broader market, driven by chronic therapies such as cardiac, diabetes, and respiratory treatments, which constitute 62% of the company's India sales.

Disclaimer: This article provides information for general knowledge purposes only and should not be construed as investment advice. Readers are encouraged to consult with a qualified financial advisor before making any investment decisions.

Related